Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar ...

New eczema drug from Eli Lilly receives FDA approval for children and adults Reuters On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020.

And more patients assigned to nemolizumab had a 75% reduction on the Eczema Area and Severity Index at week 16 as well: ARCADIA 1: 44% vs 29% ( P <0.0001) ARCADIA 2: 42% vs 30% ( P =0.0006) ...

Dec 11 (Reuters) - AnaptysBio , opens new tab will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on ...

When assessing each antihypertensive drug class individually, the largest effect size was observed for diuretic drugs (HR, 1.21) and CCB (HR, 1.16); the smallest effect sizes were for ACE ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

More than 31.6 million Americans have eczema (also called atopic dermatitis). Half of them say they're frustrated by this itchy skin condition. Creams can help relieve the itch, and steroids bring ...

Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

Nektar Therapeutics (NKTR) is headed for its best day since August 2023 after positive trial results for its eczema drug ...